// App-Quantinova.ai

DMT35 : Pregnancy Outcomes in Ofatumumab-Treated Patients with Multiple Sclerosis

Researchers

Presenter

  • Kerstin Hellwig

Principal Investigators

  • Bassem Yamout

  • Riley Bove

  • Krishna Swetha Gummuluri

  • Ulf Schulze Topphoff

  • Simone Fantaccini

  • Ronald Zielman

  • Roseanne Sullivan

  • Maria Pia Amato

  • Ruth Dobson

  • Maria Houtchens

Medical Centers

  • Harley Street Medical Center, Abu Dhabi, United Arab Emirates

  • Preventative Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

  • Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School

  • University of California, San Francisco, San Francisco, CA

  • IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

  • Department of Haematology, Royal London Hospital, Barts Health NHS Trust, London, England, United Kingdom

  • Department for Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany

  • Novartis Pharma B.V.,Amsterdam,Netherlands

  • Dept. NEUROFARBA, University of Florence, Florence, Italy

  • Novartis Pharma Corp, Basel, Switzerland

Locations

  • Switzerland

  • United States

  • Germany

  • India

  • Italy

  • United Kingdom

  • Netherlands

  • United Arab Emirates

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

  • Congenital disorder

Disease

  • Congenital anomalies

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved